Saol Therapeutics (pronounced “Sail”) is a privately-held, specialty biotech pharmaceutical company with operations in both Roswell, GA and Dublin, Ireland. Saol, focused on neuroscience (spasticity) and rare disease, is committed to providing and advancing therapeutic options for patients and the physicians treating these populations. For more information, visit www.saolrx.com.
Location: United States, Georgia, Roswell
Employees: 51-200
Founded date: 2015
Investors 2
| Date | Name | Website |
| - | Avego | avego.com |
| - | DFW Capita... | dfwcapital... |
Mentions in press and media 5
| Date | Title | Description |
| 21.04.2025 | Saol Therapeutics Announces Major Clinical Milestones | SL1009 targets a 2025 FDA decision for Pyruvate Dehydrogenase Complex Deficiency (PDCD), while SL1002 advances toward Phase III trials for osteoarthritis knee pain and spasticity ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, April 17, 2025... |
| 28.01.2025 | Saol Therapeutics announces acceptance of New Drug Application | ROSWELL, Ga, DUBLIN and HAMILTON, Bermuda, Jan. 28, 2025 — Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug App... |
| 04.12.2024 | Saol Therapeutics Announces Submission of New Drug Application | ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, Dec. 3, 2024 /PRNewswire/ — Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug ... |
| 24.03.2023 | Saol Therapeutics enhances its IP portfolio | Saol Therapeutics enhances its IP portfolio for Dichloroacetate (DCA; SL-1009) in Glioblastoma and Rare Pediatric Cancers |
| 28.09.2017 | Saol Therapeutics Acquires Three Hyperimmune Products from Aptevo Therapeutics | DFW Capital Partners is pleased to announce that its existing portfolio company, Saol Therapeutics, has acquired to acquire three marketed hyperimmune products, WinRho® SDF (Rh0(D) Immune Globulin Intravenous (Human)), HepGam B® (Hepatitis ... |